Drugs / LAS190792
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02059434 | Sep 2013 → Oct 2014 | asthma, chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAS190792 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02059434 ↗ |
| Known as | Azd 8999 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3916700 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor agonist” CHEMBL3916700 ↗ |
| Action | Inhibit | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL3916700 ↗ |
| Modality | Small molecule | — CHEMBL3916700 ↗ |
| Route | Inhaled | “administered by inhalation” NCT02059434 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL3916700 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL3916700 ↗ |